周二，H.C. Wainwright重申对Gossamer Bio ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

生物制药公司Gossamer Bio (NASDAQ: GOSS )在发布好于预期的第四季度业绩报告并更新其肺动脉高压药物候选者seralutinib的进展后，股价上涨5.4%。 公司第四季度每股亏损0.15美元，优于分析师预期的每股亏损0.17美元。营收达到934万美元，超过了702万美元的市场预期。

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a report released on Friday ...

Gossamer Bio ( ($GOSS) ) has released its Q4 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer ...

EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

Cash, cash equivalents and marketable securities as of December 31, 2024, were $294.5 million. As a result, we expect our ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...

Oracle and Disney are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual investors. These ...